Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.

Sporadic human tumors and the hereditary cancer predisposition syndrome Li-Fraumeni are frequently associated with mutations in the p53 tumor suppressor gene that compromise its ability to function as a DNA damage checkpoint. A subset of Li-Fraumeni patients with wild-type p53 alleles have mutations in chk2/hcds1, one of the genes signaling the presence of DNA damage to the p53 protein. This suggests that p53 may be kept inactive in human cancer by mutations targeting DNA damage signaling pathways. Melanoma cells are highly radioresistant, yet they express wild-type p53 protein, raising the possibility of defects in the pathways that activate p53 in response to DNA damage. We have described a chk2/hcds1-independent DNA damage signaling pathway that targets Ser-376 within the COOH terminus of p53 for dephosphorylation and leads to increased p53 functional activity. We now report that in several human melanoma cell lines that express wild-type p53, the phosphorylation state of Ser-376 was not regulated by DNA damage. In these cell lines, neither the endogenous wild-type p53 protein nor high levels of ectopic wild-type p53 led to cell cycle arrest or apoptosis. Thus, defective activation of p53 in response to DNA damage may underlie the radioresistance of human melanoma cells.

[1]  S. Elledge,et al.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.

[2]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[3]  T. Halazonetis,et al.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.

[4]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[5]  K. Isselbacher,et al.  Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.

[6]  E. Stavridi,et al.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Halazonetis,et al.  Many faces of ATM: eighth international workshop on ataxia-telangiectasia. , 1999, Biochimica et biophysica acta.

[8]  R. Ferl,et al.  Specific Interactions with TBP and TFIIB in Vitro Suggest That 14-3-3 Proteins May Participate in the Regulation of Transcription When Part of a DNA Binding Complex , 1999, Plant Cell.

[9]  T. Unger,et al.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.

[10]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[11]  R. Mcinnes,et al.  Association of the TLX-2 Homeodomain and 14-3-3η Signaling Proteins* , 1998, The Journal of Biological Chemistry.

[12]  E. Stavridi,et al.  ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins , 1998, Nature Genetics.

[13]  R. Quatrano,et al.  14-3-3 Proteins Are Part of an Abscisic Acid–VIVIPAROUS1 (VP1) Response Complex in the Em Promoter and Interact with VP1 and EmBP1 , 1998, Plant Cell.

[14]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[15]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[16]  T. Jacks,et al.  Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption , 1998, Molecular and Cellular Biology.

[17]  I. Garkavtsev,et al.  The candidate tumour suppressor p33ING1cooperates with p53 in cell growth control , 1998, Nature.

[18]  G. Wilson,et al.  Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma , 1997, The British journal of surgery.

[19]  Yoichi Taya,et al.  DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.

[20]  M. Laiho,et al.  p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle , 1997, Molecular and cellular biology.

[21]  G. Stark,et al.  The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate , 1997, Oncogene.

[22]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[23]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[24]  M. Herlyn,et al.  Adenovirus infection enhances killing of melanoma cells by a mitotoxin. , 1997, Cancer research.

[25]  G. Wahl,et al.  DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. , 1997, Cancer research.

[26]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[27]  K. Ang,et al.  Radiation therapy for malignant melanoma. , 1996, The Surgical clinics of North America.

[28]  J. Jenrette Malignant melanoma: the role of radiation therapy revisited. , 1996, Seminars in oncology.

[29]  I. Garkavtsev,et al.  Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation , 1996, Nature Genetics.

[30]  C. Thompson,et al.  Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. , 1996, Genes & development.

[31]  C. Kitanaka,et al.  Apoptosis in cancer. , 1996, Human cell.

[32]  T. Taniguchi,et al.  Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.

[33]  W. El-Deiry,et al.  In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug , 1996, International journal of cancer.

[34]  D A Scudiero,et al.  An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. , 1996, Cancer research.

[35]  T. Halazonetis,et al.  An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. , 1996, Cancer research.

[36]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[37]  L. Sandkuijl,et al.  Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.

[38]  A. Gown,et al.  p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[39]  U. Ringborg,et al.  Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma , 1995, Melanoma research.

[40]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[41]  P. Workman To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? , 1995, Human & experimental toxicology.

[42]  K. Arden,et al.  Mutation and expression of TP53 in malignant melanomas. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[43]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[44]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[45]  M. Skolnick,et al.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.

[46]  D. Fisher Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[47]  X. Montano,et al.  Analysis of p53 in human cutaneous melanoma cell lines. , 1994, Oncogene.

[48]  P. Kleihues,et al.  Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.

[49]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[50]  N. Hayward,et al.  Mutation and expression of the p53 gene in human malignant melanoma , 1994, Melanoma research.

[51]  J. Nesland,et al.  TP53 allele loss, mutations and expression in malignant melanoma. , 1994, British Journal of Cancer.

[52]  J. Giorgi,et al.  Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. , 1994, Cytometry.

[53]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[54]  A. Sober,et al.  Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma , 1993, International journal of cancer.

[55]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[56]  W. Cavenee,et al.  Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.

[57]  D. Barnes,et al.  p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.

[58]  N. Lassam,et al.  Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.

[59]  M. Melamed,et al.  Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. , 1993, Leukemia.

[60]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[61]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[62]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[63]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[64]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[65]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[66]  U. Schlegel,et al.  Mutational analysis of the human p53 gene in malignant melanoma. , 1991, Pigment cell research.

[67]  P. Nowell,et al.  Characteristics of cultured human melanocytes isolated from different stages of tumor progression. , 1985, Cancer research.

[68]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.